TG Therapeutics (TGTX) is trading lower today after a new analyst update pointed to softer near-term earnings expectations. HC Wainwright reduced its Q1 2026 earnings-per-share estimate to $0.17 from $0.24, a revision that can pressure the stock even when the long-term commercial story remains intact. (defenseworld.net)

A downward EPS revision typically implies higher operating spend, slower-than-expected margin expansion, or timing effects in revenue recognition—factors traders tend to discount quickly when a stock has recently rerated higher. With TGTX recently trading well above its longer-term moving averages, incremental caution on profitability can trigger a pullback and profit-taking on an otherwise positive product trajectory. (defenseworld.net)

The company’s core narrative remains centered on BRIUMVI’s U.S. commercialization and 2026 revenue outlook, with management previously communicating elevated 2026 revenue expectations and 2026 development milestones. Today’s move looks more like a near-term earnings/estimate reset than a fundamental break in the product thesis. (ir.tgtherapeutics.com)